Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

NCT06375005 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Cutaneous Systemic Sclerosis

Interventions

DRUG: Telitacicept
DRUG: Mycophenolate Mofetil

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University